

Substitute for form 1449A/PTO

Complete if Known

Application No.	09/525,998
Filing Date:	03/15/2000
First Named Inventor	Hauptmann
Group Art Unit	1646
Examiner Name	E. O'Hara
Attorney Docket No.	98-385-E

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T ¹¹
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		POWELL et al., "Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein specific T-cell clones correlates with encephalitogenicity," Int. Immunol. 2:539-44 (1990).	
EA		TRACEY et al., "Anti-cachectin/TNF Monoclonal Antibodies Prevent Septic Shock During Lethal Bacteraemia," Nature 330:662-664 (1987).	
EA		TSUJIMOTO et al., "Characterization and Affinity Crosslinking of Receptors for Tumor Necrosis Factor on Human Cells", Archives of Biochem. & Biophys. 249(2):563-568 (1986)	
EA		TRACEY et al., Physiological responses to cachectin, "Tumor Necrosis Factor and Related Cytotoxins pp. 88-108 (Ciba Foundation Symposium 131, Wiley, Chichester, 1987).	

Examiner
Signature

Eileen B. O'Hara

Date
Considered

RECEIVED
DEC 21 2002
TECH CENTER 1600/2900

*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.